- 5 accumulation markers appear in the recent smart-money tape.
BIOFILCHEM
NSI
Week ended 07 Aug 2026
Weekly Investor Report
Biofil Chemicals and Pharmaceuticals Limited · Healthcare · Drug Manufacturers - Specialty & Generic
Latest close
32.39 INR
1.4%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -1.4% below the Trend Line and sits at 32.7% of its 52-week range. The latest completed week returned 1.4%, after a -4.9% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 50/100. Near-term considerations: volume confirmation is below normal.
Setup score
25
out of 100
Latest Close
32.39 INR
7 Aug 2026
1W Return
1.4%
latest completed week
4W Return
-4.9%
short-term follow-through
12W Return
-0.8%
quarterly tape
Trend Breadth
11.5%
6 of 52 weeks active
Volume Ratio
0.3x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
1.4%
Latest completed week; four-week move -4.9%.
Indicator stack
6/36
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 42.12%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
50/100
2 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -1.4% below the Trend Line and sits at 32.7% of its 52-week range. The latest completed week returned 1.4%, after a -4.9% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.3x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.1812-week average 0.16
12-week confirmation
Trend active6/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure11/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership4/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.18Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
5 accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -4.9% over four weeks, -0.8% over 12 weeks, and -25.5% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year6
Trend breadth11.5%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.25Latest activity-pressure read.
Pressure change-121.1%Four-week change in activity pressure.
Leadership-8.04Latest relative-leadership reading.
RS change-88.3%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 88%
Model confidence 82%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength68/100Blend of value, momentum, and quality. Underlying universe rank 33; rank 1 is best.
Value57/100Relative valuation strength. Underlying universe rank 44; rank 1 is best.
Quality56/100Profitability and accounting quality. Underlying universe rank 45; rank 1 is best.
Momentum59/100Medium-term price momentum. Underlying universe rank 42; rank 1 is best.
Growth56/100Revenue and earnings growth. Underlying universe rank 45; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 18.9x Price divided by trailing earnings.
- Price / sales
- 1.9x Market value relative to trailing revenue.
- EV / EBITDA
- 14.9x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -1.4% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 7.6% Gross profit retained from each unit of revenue.
- Operating margin
- 1.3% Operating profit retained from revenue.
- Free-cash-flow margin
- -2.8% Free cash flow generated from revenue.
- Return on invested capital
- 1.2% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- -15.0% Latest one-year revenue growth.
- EPS growth
- 399.5% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 6/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.8x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment50/100
Weighted news tone is neutral across 2 relevant articles.
0 positive · 2 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-30.1%Distance below the 52-week high.
13-week volatility4.0%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher11 of 2615 weeks finished lower.
Best week+21.0%Week of 10 Apr.
Worst week-7.4%Week of 27 Mar.
Latest week+1.4%Week of 7 Aug.
Shape of recent returns
Strong gains2
Modest gains9
Flat weeks0
Modest losses10
Sharp losses5
Recent vol4.0%13-week weekly-return volatility.
Base vol5.5%52-week weekly-return volatility.
Up/down split20/32Count of positive and negative weeks in the 52-week window.
Average skew3.9% / -3.1%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorIN Healthcare
4-week rank- / 100
Group average1.2%
Trend breadth83.0%
Trend83.0%active weekly trend signals
MD85.0%positive activity pressure
RS73.0%positive relative leadership
Four-week leaders
IndustryIN Drug Manufacturers - Specialty & Generic
4-week rank66 / 92
Group average1.0%
Trend breadth76.1%
Trend76.1%active weekly trend signals
MD80.4%positive activity pressure
RS65.2%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape23/100
Trend, activity pressure, participation, and risk combine to a 23/100 tape read.
Indicator analysis56/100Latest 12-week confirmation: trend 6/12, activity pressure 11/12, relative leadership 4/12.
Activity pressure 0.18; No reversal markers Next-Week ExpectancyNegative 42.12%Next-week expectancy is negative with a 42.12% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors59/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 9 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment50/100Weighted news tone is neutral across 2 relevant articles.
Market Still Lacking Some Conviction On Biofil Chemicals and Pharmaceuticals Limited (NSE:BIOFILCHEM) Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 32.39 INR | 1.4% | 32.85 INR | 50.24 INR | -0.25 | -8.04 | 42.1K | Off |
| 31 Jul 2026 | 31.94 INR | -0.4% | 32.85 INR | 50.33 INR | 0.13 | -9.19 | 21.6K | Off |
| 24 Jul 2026 | 32.07 INR | -3.7% | 32.90 INR | 50.42 INR | 0.48 | -7.04 | 25.3K | On |
| 17 Jul 2026 | 33.30 INR | -2.2% | 32.96 INR | 50.51 INR | 0.90 | -6.33 | 38.1K | On |
| 10 Jul 2026 | 34.06 INR | 1.0% | 32.94 INR | 50.60 INR | 1.18 | -4.27 | 46.8K | On |
| 3 Jul 2026 | 33.71 INR | -6.5% | 32.93 INR | 50.66 INR | 1.33 | -6.07 | 9.8K | On |
| 26 Jun 2026 | 36.07 INR | 0.1% | 32.97 INR | 50.73 INR | 1.46 | 0.81 | 0 | On |
| 19 Jun 2026 | 36.05 INR | -0.6% | 33.01 INR | 50.79 INR | 1.57 | 0.49 | 35.3K | On |
| 12 Jun 2026 | 36.25 INR | 2.7% | 33.08 INR | 50.84 INR | 1.31 | 2.26 | 234.6K | Off |
| 5 Jun 2026 | 35.29 INR | 0.6% | 33.18 INR | 50.89 INR | 1.05 | 0.01 | 181.8K | Off |
| 29 May 2026 | 35.09 INR | 10.5% | 33.31 INR | 50.95 INR | 1.03 | -2.10 | 1.1M | Off |
| 22 May 2026 | 31.77 INR | -2.7% | 33.46 INR | 51.01 INR | 0.87 | -12.56 | 37.4K | Off |
| 15 May 2026 | 32.64 INR | -4.5% | 33.70 INR | 51.09 INR | 1.02 | -10.44 | 59.2K | Off |
| 8 May 2026 | 34.17 INR | 0.4% | 33.94 INR | 51.16 INR | 1.15 | -8.84 | 58.0K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.